Rag2-KO/hVEGFR2
Nomenclature
C57BL/6Smoc-Rag2em1Kdrtm2(hKDR)Smoc
Cat. NO.
NM-HU-200280
Strain State
Embryo cryopreservation
Model Description
Validation Data
Fig1. In vivo anti-tumor response of Cyramza and Avastin in the treatment of gastric cancer PDX model(GA2419)in the immunodeficient Rag2-KO/hKDR mice. (Completed in collaboration with CrownBio)
(A)Breeding scheme for development of Rag2-KO/hKDR mice; (B) Tumor growth curves upon treatment of Cyramza and Avastin; (C) Body weight change upon treatment.
Fig2. In vivo anti-tumor response of Cyramza in thetreatment of liver cancer PDX model(LI0612)in the im-munodeficient Rag2-KO/hKDR mice. (Completed in collaboration with CrownBio)
(A)Tumor blood vesselstaining via anti-human VEGFR2 IHC; (B) Tumor growth curves upon Cyramza treatment; (C)Body weight change upon treatment.
You may also like
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.
Learn moreSMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.
Learn more
